Search

Recursion Pharmaceuticals Inc

Open

SectorGezondheidszorg

3.63 5.83

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.61

Max

3.66

Belangrijke statistieken

By Trading Economics

Inkomsten

-14M

-131M

Verkoop

1.2M

7.7M

EPS

-0.25

Winstmarge

-1,708.018

Werknemers

600

EBITDA

-10M

-113M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+77.13% upside

Dividenden

By Acuity

Volgende Winsten

4 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

135M

1.8B

Vorige openingsprijs

-2.2

Vorige sluitingsprijs

3.63

Nieuwssentiment

By Acuity

34%

66%

71 / 339 Rangschikking in Healthcare

Recursion Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 sep 2026, 20:08 UTC

Recursion Pharmaceuticals shares are higher today, continuing an upward trend since Thursday's close, amid broader market dynamics following a strong jobs report.

3 sep 2026, 23:21 UTC

Correlated Moves

Recursion Pharmaceuticals Inc. shares declined in after-market trading, following a peak shortly after the market closed and amid broader market weakness.

2 sep 2026, 23:06 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market trading. The decline comes amid a weaker ADP private payrolls report impacting overall market sentiment.

1 sep 2026, 20:09 UTC

Recursion Pharmaceuticals Inc. shares are lower, following broader market declines amid rising oil prices and increasing U.S. Treasury yields. No specific company news was identified.

31 aug 2026, 23:06 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours. Market sentiment reflects recent comments from Federal Reserve Chair Kevin Warsh on inflation and interest rates.

28 aug 2026, 23:51 UTC

Recursion Pharmaceuticals Inc shares are higher in after-market hours, following three consecutive lower finishes. No specific news was identified to explain the movement.

27 aug 2026, 23:02 UTC

Recursion Pharmaceuticals Inc shares are trading higher in after-market hours. No specific news was identified to explain the price movement.

26 aug 2026, 20:08 UTC

Correlated Moves

Recursion Pharmaceuticals is declining amid a broader downturn in the Biotechnology sub-sector, with the ARK Genomic Revolution ETF also experiencing losses.

25 aug 2026, 23:01 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market trading, with no specific news identified to explain the decline. The stock remains above its 20-day moving average.

24 aug 2026, 20:02 UTC

News
Correlated Moves

Recursion Pharmaceuticals Inc shares are lower amid broader market declines, with analysts rating the stock as a "Hold" and price targets between $5.30 and $10.00.

21 aug 2026, 20:06 UTC

Recursion Pharmaceuticals Inc shares are higher during Friday's session, reflecting strong momentum since Thursday's close amid favorable conditions in the biotechnology sector.

20 aug 2026, 20:06 UTC

Social Media
Correlated Moves

Recursion Pharmaceuticals Inc shares are lower today, reflecting broader market trends. The stock's decline aligns with weakness in correlated assets.

19 aug 2026, 23:01 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours after a volatile session, declining from the upper end of its one-month range.

18 aug 2026, 20:04 UTC

Correlated Moves

Recursion Pharmaceuticals Inc shares are lower today amid broader market pressures on small-cap stocks and rising U.S. Treasury yields affecting sentiment.

17 aug 2026, 19:36 UTC

Correlated Moves
News

Recursion Pharmaceuticals shares decline as Morgan Stanley cuts the price target to $5.30 from $5.50, reflecting ongoing valuation concerns.

12 aug 2026, 19:56 UTC

Recursion Pharmaceuticals Inc is trading lower, reflecting a decline from Tuesday's close. The stock remains above its 20-day moving average despite today's pullback.

11 aug 2026, 19:36 UTC

News

Recursion Pharmaceuticals Inc. is higher today amid positive market sentiment and over $500 million in milestone payments from partnerships with Genentech/Roche and Sanofi.

10 aug 2026, 20:06 UTC

Social Media

Recursion Pharmaceuticals Inc is higher Monday amid ongoing interest, despite social media concerns about its clinical pipeline and integration challenges with Exscientia.

7 aug 2026, 23:26 UTC

Recursion Pharmaceuticals Inc. shares have been roughly flat in after-market trading, with minimal fluctuations since Friday's close. The stock remains above its 20-day moving average.

6 aug 2026, 23:26 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours, reflecting a slight decline since Thursday's close amid a strengthening U.S. Dollar.

5 aug 2026, 23:41 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours, amid declining sentiment in US markets despite positive momentum in Asian indices.

4 aug 2026, 23:31 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours following a volatile session with no specific news to explain the movement.

3 aug 2026, 20:03 UTC

Correlated Moves
News

Recursion Pharmaceuticals Inc shares are higher amid strong market sentiment, supported by a rise in the Russell 2000 Index and notable intraday volatility.

31 jul 2026, 23:32 UTC

News

Recursion Pharmaceuticals Inc shares are lower in after-market hours, reflecting broader market trends amid mixed performance among major tech stocks and upcoming economic data.

30 jul 2026, 23:26 UTC

Recursion Pharmaceuticals Inc. shares were roughly flat in after-market hours, trading within a narrow range since Thursday's close, significantly below its 20-day moving average.

29 jul 2026, 22:51 UTC

Recursion Pharmaceuticals Inc is higher in after-market trading, reflecting broader market gains amid the Federal Reserve's decision to maintain interest rates.

28 jul 2026, 23:11 UTC

Correlated Moves

Recursion Pharmaceuticals Inc shares declined in after-market hours, influenced by a broader market downturn and declines in tech stocks amid AI investment concerns.

27 jul 2026, 23:46 UTC

Correlated Moves

Recursion Pharmaceuticals Inc shares are lower in after-market trading, reflecting broader market trends despite gains in the DAX 30 Index amid mixed results across indices.

24 jul 2026, 23:11 UTC

Recursion Pharmaceuticals Inc shares rose during after-market hours, gaining momentum despite being near the lower end of their one-month trading range.

23 jul 2026, 19:16 UTC

Recursion Pharmaceuticals Inc. shares are trading roughly flat, remaining below their 20-day moving average amid limited upward momentum in broader market dynamics.

Peer Vergelijking

Prijswijziging

Recursion Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

77.13% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 6.43 USD  77.13%

Hoogste 8 USD

Laagste 5.3 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Recursion Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

4 ratings

1

Buy

3

Hold

0

Sell

Sentiment

By Acuity

71 / 339 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
help-icon Live chat